ANI PHARMACEUTICALS INC (ANIP) Stock
4 of the hedge funds AlphaScala tracks reported ANIP in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $41.99M. Company insiders reported 0 open-market buys and 10 sales on SEC Form 4 in the 90 days to Nov 10, 2026.
Which hedge funds own ANIP?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 507K | $41.99M | -14% |
| D.E. Shaw David Shaw | 175K | $14.46M | -18% |
| Citadel Ken Griffin | 96K | $7.95M | -17% |
| Renaissance Technologies Jim Simons (founder) | 64K | $5.27M | -66% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are ANI PHARMACEUTICALS INC insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 29, 26 | Carey Stephen P. | SVP & CFO | SELL | 2.9K | $208K |
| Oct 15, 26 | Lalwani Nikhil | PRESIDENT & CEO | SELL | 5.4K | $388K |
| Oct 13, 26 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | SELL | 500 | $37K |
| Sep 29, 26 | Carey Stephen P. | SVP & CFO | SELL | 2.9K | $208K |
| Sep 15, 26 | Lalwani Nikhil | PRESIDENT & CEO | SELL | 5.4K | $383K |
| Sep 14, 26 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | SELL | 500 | $35K |
| Sep 11, 26 | Thoma Jeanne | Director | SELL | 1.0K | $72K |
| Aug 31, 26 | Carey Stephen P. | SVP & CFO | SELL | 2.9K | $207K |
| Aug 25, 26 | Lalwani Nikhil | PRESIDENT & CEO | SELL | 5.4K | $401K |
| Aug 13, 26 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | SELL | 500 | $38K |
SEC Form 4 filings as of Nov 10, 2026
See cluster-buy signals across all tickers →ANIP price chart
Powered by TradingViewWhat does ANI PHARMACEUTICALS INC do?
ANI Pharmaceuticals Inc. is a diversified biopharmaceutical company that develops, manufactures, and markets branded and generic prescription pharmaceuticals. It specializes in a range of dosage forms, including liquid, powder, oral solid-dose products, injectables, softgel capsules, semi-solids, topicals, and controlled substances. The company operates through key segments: Rare Disease, featuring novel therapeutics in ophthalmology, rheumatology, nephrology, neurology, and pulmonology, such as Purified Cortrophin Gel, ILUVIEN, and YUTIQ; Generics, leveraging R&D expertise and U.S.-based manufacturing for products like Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone, and Vancomycin; and Established Brands. ANI Pharmaceuticals Inc. focuses on areas like narcotics, oncolytics, hormones, steroids, and complex formulations including extended-release and combination products. Primarily serving the United States and Canada, it emphasizes high-quality therapeutics through operational excellence and North American manufacturing capabilities. Founded in 2001 and headquartered in Baudette, Minnesota, ANI Pharmaceuticals Inc. plays a vital role in addressing patient needs across specialized pharmaceutical markets.